Related Experiment Video
Updated: Feb 25, 2026
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
Potential New Non-Invasive Therapy Using Artificial Oxygen Carriers for Pre-Eclampsia
Hidenobu Ohta1,2, Maiko Kaga3, Heng Li4
1Department of Psychophysiology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8553, Japan. hideohta@ncnp.go.jp.
Abstract:
The molecular mechanisms of pre-eclampsia are being increasingly clarified in animals and humans. With the uncovering of these mechanisms, preventive therapy strategies using chronic infusion of adrenomedullin, vascular endothelial growth factor-121 (VEGF-121), losartan, and sildenafil have been proposed to block narrow spiral artery formation in the placenta by suppressing related possible factors for pre-eclampsia. However, although such preventive treatments have been partly successful, they have failed in ameliorating fetal growth restriction and carry the risk of possible side-effects of drugs on pregnant mothers. In this study, we attempted to develop a new symptomatic treatment for pre-eclampsia by directly rescuing placental ischemia with artificial oxygen carriers (hemoglobin vesicles: HbV) since previous data indicate that placental ischemia/hypoxia may alone be sufficient to lead to pre-eclampsia through up-regulation of sFlt-1, one of the main candidate molecules for the cause of pre-eclampsia. Using a rat model, the present study demonstrated that a simple treatment using hemoglobin vesicles for placental ischemia rescues placental and fetal hypoxia, leading to appropriate fetal growth. The present study is the first to demonstrate hemoglobin vesicles successfully decreasing maternal plasma levels of sFlt-1 and ameliorating fetal growth restriction in the pre-eclampsia rat model (p < 0.05, one-way ANOVA). In future, chronic infusion of hemoglobin vesicles could be a potential effective and noninvasive therapy for delaying or even alleviating the need for Caesarean sections in pre-eclampsia.
Insights
This study introduces hemoglobin vesicles (HbV) as a novel treatment for pre-eclampsia, effectively reducing placental ischemia and improving fetal growth in a rat model. HbV therapy shows promise in decreasing pre-eclampsia markers and alleviating fetal growth restriction.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Biomedical Engineering
Background:
- Pre-eclampsia mechanisms are increasingly understood, leading to proposed preventive therapies.
- Current preventive strategies face limitations, including failure to ameliorate fetal growth restriction and potential maternal side effects.
- Placental ischemia and hypoxia are implicated in pre-eclampsia pathogenesis, potentially via soluble Fms-like tyrosine kinase-1 (sFlt-1) upregulation.
Purpose of the Study:
- To develop and evaluate a new symptomatic treatment for pre-eclampsia by directly addressing placental ischemia.
- To investigate the efficacy of artificial oxygen carriers, specifically hemoglobin vesicles (HbV), in a rat model of pre-eclampsia.
- To assess HbV's impact on placental and fetal hypoxia, fetal growth, and key pre-eclampsia biomarkers like sFlt-1.
Main Methods:
- Utilized a rat model to simulate pre-eclampsia conditions.
- Administered hemoglobin vesicles (HbV) to treat placental ischemia.
- Measured placental and fetal oxygen levels, fetal growth parameters, and maternal plasma sFlt-1 concentrations.
Main Results:
- Hemoglobin vesicle treatment successfully rescued placental and fetal hypoxia, promoting appropriate fetal growth.
- This study is the first to demonstrate HbV's ability to decrease maternal plasma sFlt-1 levels.
- HbV administration significantly ameliorated fetal growth restriction in the pre-eclampsia rat model (p < 0.05).
Conclusions:
- Hemoglobin vesicles represent a potential effective and noninvasive symptomatic therapy for pre-eclampsia.
- HbV treatment directly addresses placental ischemia, a key factor in pre-eclampsia.
- Future research may explore chronic HbV infusion for delaying or reducing the need for Cesarean sections in pre-eclampsia.
More Related Videos
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
14:28Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care
Published on: May 10, 2024
